Cargando…

Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis

Chronic tissue inflammation often results in fibrosis characterized by the accumulation of extracellular matrix components remodeling normal tissue architecture and function. Recent studies have suggested common immune mechanisms despite the complexity of the interactions between tissue-specific fib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Vipin, Hertz, Marc, Agro, Albert, Byrne, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561218/
https://www.ncbi.nlm.nih.gov/pubmed/37818376
http://dx.doi.org/10.3389/fimmu.2023.1260503
_version_ 1785117873484595200
author Kumar, Vipin
Hertz, Marc
Agro, Albert
Byrne, Adam J.
author_facet Kumar, Vipin
Hertz, Marc
Agro, Albert
Byrne, Adam J.
author_sort Kumar, Vipin
collection PubMed
description Chronic tissue inflammation often results in fibrosis characterized by the accumulation of extracellular matrix components remodeling normal tissue architecture and function. Recent studies have suggested common immune mechanisms despite the complexity of the interactions between tissue-specific fibroblasts, macrophages, and distinct immune cell populations that mediate fibrosis in various tissues. Natural killer T (NKT) cells recognizing lipid antigens bound to CD1d molecules have been shown to play an important role in chronic inflammation and fibrosis. Here we review recent data in both experimental models and in humans that suggest a key role of type 1 invariant NKT (iNKT) cell activation in the progression of inflammatory cascades leading to recruitment of neutrophils and activation of the inflammasome, macrophages, fibroblasts, and, ultimately, fibrosis. Emerging evidence suggests that iNKT-associated mechanisms contribute to type 1, type 2 and type 3 immune pathways mediating tissue fibrosis, including idiopathic pulmonary fibrosis (IPF). Thus, targeting a pathway upstream of these immune mechanisms, such as the inhibition of iNKT activation, may be important in modulating various fibrotic conditions.
format Online
Article
Text
id pubmed-10561218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105612182023-10-10 Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis Kumar, Vipin Hertz, Marc Agro, Albert Byrne, Adam J. Front Immunol Immunology Chronic tissue inflammation often results in fibrosis characterized by the accumulation of extracellular matrix components remodeling normal tissue architecture and function. Recent studies have suggested common immune mechanisms despite the complexity of the interactions between tissue-specific fibroblasts, macrophages, and distinct immune cell populations that mediate fibrosis in various tissues. Natural killer T (NKT) cells recognizing lipid antigens bound to CD1d molecules have been shown to play an important role in chronic inflammation and fibrosis. Here we review recent data in both experimental models and in humans that suggest a key role of type 1 invariant NKT (iNKT) cell activation in the progression of inflammatory cascades leading to recruitment of neutrophils and activation of the inflammasome, macrophages, fibroblasts, and, ultimately, fibrosis. Emerging evidence suggests that iNKT-associated mechanisms contribute to type 1, type 2 and type 3 immune pathways mediating tissue fibrosis, including idiopathic pulmonary fibrosis (IPF). Thus, targeting a pathway upstream of these immune mechanisms, such as the inhibition of iNKT activation, may be important in modulating various fibrotic conditions. Frontiers Media S.A. 2023-09-25 /pmc/articles/PMC10561218/ /pubmed/37818376 http://dx.doi.org/10.3389/fimmu.2023.1260503 Text en Copyright © 2023 Kumar, Hertz, Agro and Byrne https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kumar, Vipin
Hertz, Marc
Agro, Albert
Byrne, Adam J.
Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
title Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
title_full Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
title_fullStr Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
title_full_unstemmed Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
title_short Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
title_sort type 1 invariant natural killer t cells in chronic inflammation and tissue fibrosis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561218/
https://www.ncbi.nlm.nih.gov/pubmed/37818376
http://dx.doi.org/10.3389/fimmu.2023.1260503
work_keys_str_mv AT kumarvipin type1invariantnaturalkillertcellsinchronicinflammationandtissuefibrosis
AT hertzmarc type1invariantnaturalkillertcellsinchronicinflammationandtissuefibrosis
AT agroalbert type1invariantnaturalkillertcellsinchronicinflammationandtissuefibrosis
AT byrneadamj type1invariantnaturalkillertcellsinchronicinflammationandtissuefibrosis